Effectiveness of innovative gene therapy treatment demonstrated in canine model of DMD

2014-11-13

(Press-News.org) Duchenne muscular dystrophy is the most common neuromuscular disease of children (affecting 1 boy in 3500-5000 births). It is caused by a genetic defect in the DMD gene residing on the X chromosome, which results in the absence of the dystrophin protein essential to the proper functioning of muscles. The treatment being developed by researchers at Atlantic Gene Therapies, Généthon and the Institute of Myology, is based on the use of an AAV vector (Adeno Associated Virus) carrying a transgene for the skipping of a specific exon which allows functional dystrophin production in the muscle of the patient.

Safety, efficacy and stability of the treatment in dogs In GRMD (Golden Retriever Muscular Dystrophy) dogs the treatment aimed at skipping exons 6, 7 and 8 of the dystrophin gene. The product was given by loco-regional administration in the forelegs of 18 dogs who were followed for 3.5 months after injection. It was well tolerated by all treated dogs; no immune response against the synthesized dystrophin was observed. Exon skipping resulted in high levels of expression of dystrophin in the treated muscles. The results of this treatment also indicate that, once injected into the muscle tissue a prolonged and stable effect is produced over the observation time of the study and, unlike antisense oligonucleotides already used clinically for exon skipping, it does not need to be re- administered regularly. The synthesis of "new" dystrophin is dependent on the dose of vector injected: the higher the dose, the greater the exon skipping is effective. Muscle strength also increases with dose. 80% of muscle fibers expressed the "new" dystrophin at the highest dose. This is a very encouraging result because a minimum of 40% of dystrophin in muscle fibers is believed to be necessary for the muscle force to be significantly improved.

A phase I/II clinical trial phase These results open the way for a phase I / II clinical trial by loco-regional administration in the upper limb of non-ambulatory Duchenne muscular dystrophy patients which are amenable to treatment by the specific skipping of exon 53. The regulatory toxicology and biodistribution studies have just ended and the filing of an application with regulatory authorities is planned for 2015.

INFORMATION:

Atlantic Gene Therapies, Genethon and the Institute of Myology are members of the Institute of Biotherapy for Rare Diseases created by the AFM-Telethon. With over 600 experts in Nantes, Paris and Evry it is a unique and potent force for the development of gene therapies for rare diseases.

This work also received funding under the ADNA (Advanced Diagnostics for New Therapeutic Approaches) program which is dedicated to the development of personalized medicine and supported by the Public Investment Bank.

Publication : Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients Caroline Le Guiner1,2, Marie Montus2, Laurent Servais3, Yan Cherel4, Virginie Francois1, Jean-Laurent Thibaud5,6, Claire Wary5, Béatrice Matot5, Thibaut Larcher4, Lydie Guigand4, Maeva Dutilleul4, Claire Domenger1, Marine Allais1, Maud Beuvin7, Amélie Moraux8, Johanne Le Duff1, Marie Devaux1, Nicolas Jaulin1, Mickaël Guilbaud1, Virginie Latournerie2, Philippe Veron2, Sylvie Boutin2, Christian Leborgne2, Diana Desgue2, Jack-Yves Deschamps4,9, Sophie Moullec9, Yves Fromes9, Adeline Vulin10, Richard H Smith11, Nicolas Laroudie2, Frédéric Barnay-Toutain2, Christel Rivière2, Stéphanie Bucher2, Thanh-Hoa Le2, Nicolas Delaunay2, Mehdi Gasmi2, Robert M Kotin11, Gisèle Bonne7,12, Oumeya Adjali1, Carole Masurier2, Jean-Yves Hogrel8, Pierre Carlier5, Philippe Moullier1,2,13 and Thomas Voit7 1Atlantic Gene Therapies, INSERM UMR 1089, Université de Nantes, CHU de Nantes, Nantes, France; 2Généthon, Evry, France; 3Institut de Myologie, Service of Clinical Trials and Databases, Paris, France; 4Atlantic Gene Therapies, INRA UMR 703, ONIRIS, Nantes, France; 5Institut de Myologie, Laboratoire RMN, AIM & CEA, Paris, France; 6UPR de Neurobiologie, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France; 7Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre and Marie Curie Paris 6 UPMC-INSERM UMR 974, CNRS FRE 3617, Paris, France; 8Institut de Myologie, Neuromuscular Physiology and Evaluation Laboratory, Paris, France; 9Atlantic Gene Therapies, Centre de Boisbonne, ONIRIS, Nantes, France; 10Research Institute, Center for Gene Therapy, Nationwide Childrens Hospital, Columbus, Ohio, USA; 11Laboratory of Molecular Virology and Gene Therapy, National Heart Lung and Blood Institute, National Institute of Health, Bethesda, Maryland, USA; 12AP-HP, Groupe Hospitalier Pitié-Salpêtrière,U.F. Cardiogénétique et Myogénétique, Service de Biochimie Métabolique, Paris, France; 13Department of Molecular Genetics and Microbiology,University of Florida, Gainesville, Florida, USA

About AFM-Téléthon - http://www.afm-telethon.fr The French Muscular Dystrophy Association (AFM) federates patients with neuromuscular diseases (genetic diseases that causing progressive irreversible muscle atrophy lead to death) and their parents. Thanks in great part to donations from France's annual Telethon (€89,3 million in 2013), the AFM-Telethon has become a major player in biomedical research for rare diseases in France and worldwide. It currently funds 34 clinical trials in different genetic diseases affecting the eye, blood, brain, immune system, and muscles... Thanks to its Genethon research lab, the AFM-Telethon stands out through its unique ability to produce and test its own gene-based medicines.

About Généthon - http://www.genethon.fr Created and funded by the AFM-Telethon, Généthon's mission is to make available to patients innovative gene therapy treatments. Having played a pioneering role in deciphering the human genome, Généthon is today, with more than 200 scientists, physicians, engineers and regulatory affairs specialists, an international research and development center for preclinical and clinical gene therapy treatments for rare diseases. Généthon also has the largest site in the world for GMP production of gene therapy products, Généthon Bioprod. Généthon received the 2012 Prix Galien for Pharmaceutical Research (France) and was thus the first non-profit laboratory to receive this prestigious award.

About Atlantic Gene Therapies - http://www.atlantic-gene-therapies.fr Created in 2012 under the leadership of the AFM-Telethon, Atlantic Gene Therapies has the capacity to support projects from research through clinical trials thanks to its expertise and dedicated translational research platforms. 85 experts from this Nantes center develop these gene therapy strategies including notably genetic diseases of the retina, muscles and central nervous system.

About the Institute of Myology - http://www.institut-myologie.org Established in 1996, the Institute of Myology is located in the heart of the Paris Pitié-Salpêtrière hospital. Its 280 physicians, scientists, engineers and nurses provide basic and clinical research activities, medical consultations for patients with neuromuscular diseases and a teaching activity. It is an international center of excellence for clinical trials in neuromuscular diseases.

Press contacts Stéphanie Bardon / Gaëlle Monfort - +33(0)1 69 47 28 59 - presse@afm-telethon.fr

ELSE PRESS RELEASES FROM THIS DATE:

New process isolates promising material

2014-11-13

After graphene was first produced in the lab in 2004, thousands of laboratories began developing graphene products worldwide. Researchers were amazed by its lightweight and ultra-strong properties. Ten years later, scientists now search for other materials that have the same level of potential. "We continue to work with graphene, and there are some applications where it works very well," said Mark Hersam, the Bette and Neison Harris Chair in Teaching Excellence at Northwestern University's McCormick School of Engineering and Applied Science, who is a graphene expert. ...

High blood pressure puts 1 in 4 Nigerians at risk, study says

2014-11-13

High blood pressure - already a massive hidden killer in Nigeria - is set to sharply rise as the country adopts western lifestyles, a study suggests. Researchers who conducted the first up-to-date nationwide estimate of the condition in Nigeria warn that this will strain the country's already-stretched health system. Increased public awareness, lifestyle changes, screening and early detection are vital to tackle the increasing threat of the disease, they say. High blood pressure - also known as hypertension - is twice as high in Nigeria compared with other East ...

African Americans at greater risk from stroke and other cerebrovascular diseases

2014-11-13

Researchers at The University of Texas have found that compared to Caucasian Americans, African Americans have impaired blood flow regulation in the brain that could contribute to a greater risk of cerebrovascular diseases such as stroke, transient ischaemic attack ("mini stroke"), subarachnoid haemorrhage or vascular dementia. These findings were published in Experimental Physiology, the journal of The Physiological Society. Cerebrovascular diseases can result from reduced blood flow in affected areas of the brain. It is still unclear why African Americans are at higher ...

Tiny needles offer potential new treatment for two major eye diseases

2014-11-13

Needles almost too small to be seen with the unaided eye could be the basis for new treatment options for two of the world's leading eye diseases: glaucoma and corneal neovascularization. The microneedles, ranging in length from 400 to 700 microns, could provide a new way to deliver drugs to specific areas within the eye relevant to these diseases. By targeting the drugs only to specific parts of the eye instead of the entire eye, researchers hope to increase effectiveness, limit side effects, and reduce the amount of drug needed. For glaucoma, which affects about 2.2 ...

Novel cancer vaccine approach for brain tumors

2014-11-13

(PHILADELPHIA) - Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). Researchers at Thomas Jefferson University have been working on a cancer vaccine that would extend that survival by activating the patient's immune system to fight the brain tumor. A study published online November 13th in the journal Cancer Immunology, Immunotherapy drilled down to the cellular and molecular mechanisms behind the vaccine, paving the way for further development ...

Premature infants exposed to unsafe levels of chemical in medical products

2014-11-13

Hospitalized premature infants are exposed to unsafe levels of a chemical found in numerous medical products used to treat them, raising questions about whether critically ill newborns may be adversely affected by equipment designed to help save their lives. The chemical, di(2-ethylhexyl)phthalate (DEHP), is used to increase flexibility of many plastic devices. These products, made from polyvinyl chloride (PVC), include most intravenous tubing, catheters, endotracheal tubes, and fluid and blood product bags. DEHP doesn't bind chemically to PVC, and is able to leach into ...

Use of private social media affects work performance

2014-11-13

In a new study, Use of Social Network Sites at Work: Does it Impair Performance?, Postdoctoral Fellow Cecilie Schou Andreassen and colleagues at the University of Bergen's (UiB) Department of Psychosocial Science looked at the consequences of the use of social media during working hours. Every day, more than one billion people worldwide use social media. This habit has also invaded the workplace, as some research reports that four out of five employees use social media for private purpose during working hours. Surprisingly, although this type of distraction may potentially ...

Genetic testing could improve breast cancer prevention

2014-11-13

Scientists used mathematical models to show that analysing genetic data, alongside a range of other risk factors, could substantially improve the ability to flag up women at highest risk of developing breast cancer. Their study showed that prevention strategies could be improved by testing not only as currently for major cancer predisposition genes such as BRCA1 and BRCA2 - which identify a small percentage of women at very high risk - but also by factoring in data on multiple gene variants that individually have only a small effect on risk, but are more common in the ...

How the breast cancer cells transform normal cells into tumoral ones?

2014-11-13

Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth. What are exosomes? Exosomes are small vesicles which are secreted by all cells and contain proteins and messenger RNAs and microRNAs. At first it was thought that only functioned ...

Combatting illegal fishing in offshore marine reserves

2014-11-13

Researchers at the ARC Centre of Excellence for Coral Reef Studies (Coral CoE) at James Cook University in Australia have found a way to predict illegal fishing activities to help authorities better protect marine reserves. Marine reserves are the most common strategy used to protect and maintain marine ecosystems around the world. The International Convention of Biological Diversity aims to have 10 per cent of the world's marine areas protected by 2020. Many countries are contributing to this target by protecting remote, offshore areas. For example, the United ...

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Effectiveness of innovative gene therapy treatment demonstrated in canine model of DMD

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: